Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-04-20
Target enrollment:
Participant gender:
Summary
Neoadjuvant therapy with penpulimab combined with anlotinib;with surgery within 4-6 weeks
after drug withdrawal;Adjuvant therapy within 4-12 weeks after surgery